GTHX Fundamental Analysis - G1 THERAPEUTICS INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to GTHX. GTHX was compared to 536 industry peers in the Biotechnology industry. GTHX has a bad profitability rating. Also its financial health evaluation is rather negative. GTHX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GTHX has reported negative net income.

In the past year GTHX has reported a negative cash flow from operations.

GTHX had negative earnings in each of the past 5 years.

In the past 5 years GTHX always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -45.36%, GTHX perfoms like the industry average, outperforming 52.20% of the companies in the same industry.

GTHX has a Return On Equity of -182.03%. This is in the lower half of the industry: GTHX underperforms 67.14% of its industry peers.

		Industry Rank	Sector Rank
ROA	-45.36%
ROE	-182.03%
ROIC	N/A

ROA(3y)-58.78%

ROA(5y)-52.55%

ROE(3y)-151.24%

ROE(5y)-111.52%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of GTHX (89.44%) is better than 92.44% of its industry peers.

GTHX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	89.44%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GTHX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for GTHX has been increased compared to 1 year ago.

Compared to 5 years ago, GTHX has more shares outstanding

The debt/assets ratio for GTHX is higher compared to a year ago.

2.2 Solvency

GTHX has an Altman-Z score of -8.24. This is a bad value and indicates that GTHX is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -8.24, GTHX is doing worse than 72.76% of the companies in the same industry.

A Debt/Equity ratio of 1.34 is on the high side and indicates that GTHX has dependencies on debt financing.

GTHX has a Debt to Equity ratio of 1.34. This is amonst the worse of the industry: GTHX underperforms 80.14% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.34
Debt/FCF	N/A
Altman-Z	-8.24

ROIC/WACCN/A

WACC11.45%

2.3 Liquidity

GTHX has a Current Ratio of 2.48. This indicates that GTHX is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 2.48, GTHX is not doing good in the industry: 71.53% of the companies in the same industry are doing better.

GTHX has a Quick Ratio of 2.12. This indicates that GTHX is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 2.12, GTHX is not doing good in the industry: 73.81% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	2.48
Quick Ratio	2.12

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GTHX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.71%, which is quite impressive.

Looking at the last year, GTHX shows a very negative growth in Revenue. The Revenue has decreased by -34.74% in the last year.

GTHX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.13% yearly.

EPS 1Y (TTM)49.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-171.43%

Revenue 1Y (TTM)-34.74%

Revenue growth 3Y22.13%

Revenue growth 5YN/A

Sales Q2Q%-60.97%

3.2 Future

Based on estimates for the next years, GTHX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.36% on average per year.

Based on estimates for the next years, GTHX will show a quite strong growth in Revenue. The Revenue will grow by 15.53% on average per year.

EPS Next Y55.71%

EPS Next 2Y43.4%

EPS Next 3Y30.77%

EPS Next 5Y20.36%

Revenue Next Year-8.96%

Revenue Next 2Y8.16%

Revenue Next 3Y10.3%

Revenue Next 5Y15.53%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GTHX. In the last year negative earnings were reported.

Based on the Price/Forward Earnings ratio of 133.52, the valuation of GTHX can be described as expensive.

GTHX's Price/Forward Earnings ratio is rather cheap when compared to the industry. GTHX is cheaper than 90.86% of the companies in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 23.15, GTHX is valued quite expensively.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	133.52

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GTHX does not grow enough to justify the current Price/Earnings ratio.

A more expensive valuation may be justified as GTHX's earnings are expected to grow with 30.77% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y43.4%

EPS Next 3Y30.77%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GTHX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

G1 THERAPEUTICS INC

NASDAQ:GTHX (9/17/2024, 8:10:49 PM)

After market: 7.14 -0.01 (-0.14%)

7.15

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-08 2024-08-08/bmo

Earnings (Next)10-30 2024-10-30/amc

Inst Owners1.72%

Inst Owner Change-96.06%

Ins Owners13.3%

Ins Owner Change0%

Market Cap377.23M

Analysts74.55

Price Target7.29 (1.96%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)22.61%

Min EPS beat(2)4.63%

Max EPS beat(2)40.58%

EPS beat(4)3

Avg EPS beat(4)16.53%

Min EPS beat(4)-4.3%

Max EPS beat(4)40.58%

EPS beat(8)7

Avg EPS beat(8)33.92%

EPS beat(12)10

Avg EPS beat(12)23.38%

EPS beat(16)14

Avg EPS beat(16)22.11%

Revenue beat(2)0

Avg Revenue beat(2)-3.93%

Min Revenue beat(2)-6.99%

Max Revenue beat(2)-0.87%

Revenue beat(4)1

Avg Revenue beat(4)-2.9%

Min Revenue beat(4)-15.25%

Max Revenue beat(4)11.53%

Revenue beat(8)4

Avg Revenue beat(8)6.13%

Revenue beat(12)7

Avg Revenue beat(12)4.65%

Revenue beat(16)10

Avg Revenue beat(16)136.37%

PT rev (1m)58.89%

PT rev (3m)-15.88%

EPS NQ rev (1m)0%

EPS NQ rev (3m)24.07%

EPS NY rev (1m)-2.21%

EPS NY rev (3m)24.34%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0.2%

Revenue NY rev (1m)2.96%

Revenue NY rev (3m)1.77%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	133.52
P/S	6.48
P/FCF	N/A
P/OCF	N/A
P/B	15.34
P/tB	15.34
EV/EBITDA	N/A

EPS(TTM)-0.86

EYN/A

EPS(NY)0.05

Fwd EY0.75%

FCF(TTM)-0.71

FCFYN/A

OCF(TTM)-0.71

OCFYN/A

SpS1.1

BVpS0.47

TBVpS0.47

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-45.36%
ROE	-182.03%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	89.44%
FCFM	N/A

ROA(3y)-58.78%

ROA(5y)-52.55%

ROE(3y)-151.24%

ROE(5y)-111.52%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.59

Health

		Industry Rank	Sector Rank
Debt/Equity	1.34
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.48
Quick Ratio	2.12
Altman-Z	-8.24

F-Score3

WACC11.45%

ROIC/WACCN/A

Cap/Depr(3y)32.08%

Cap/Depr(5y)N/A

Cap/Sales(3y)0.33%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)49.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-171.43%

EPS Next Y55.71%

EPS Next 2Y43.4%

EPS Next 3Y30.77%

EPS Next 5Y20.36%

Revenue 1Y (TTM)-34.74%

Revenue growth 3Y22.13%

Revenue growth 5YN/A

Sales Q2Q%-60.97%

Revenue Next Year-8.96%

Revenue Next 2Y8.16%

Revenue Next 3Y10.3%

Revenue Next 5Y15.53%

EBIT growth 1Y43.18%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year44.15%

EBIT Next 3Y133.69%

EBIT Next 5Y24.98%

FCF growth 1Y74.29%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y74.2%

OCF growth 3YN/A

OCF growth 5YN/A

G1 THERAPEUTICS INC (GTHX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens